Real-World Assessment of Weight Change in African American Females and Hispanics with HIV-1 After Initiating Integrase Strand-Transfer Inhibitors or Protease Inhibitors

Yen-Wen Chen*, David Anderson, Christopher D. Pericone, Prina Donga

Janssen Scientific Affairs, LLC, Titusville, NJ, USA

INTRODUCTION

At the end of 2019, the Centers for Disease Control and Prevention reported 36,000 new diagnoses of HIV and >1 million people living with HIV (PLWH) in the United States.1 Moreover, African American

and Hispanics are disproportionately affected by HIV, accounting for 40% and 25% of PLWH in the United States, respectively,1 and having generally poorer outcomes than white PLWH, including lower rates of being on antiretroviral (ARV) treatment or achieving viral load suppression.2 As another consideration in HIV care, as the
life expectancy of PLWH has increased due to ARV therapies, the proportion of PLWH ≥50 years old has increased from 46% in 2015 to 52% in 2019. As the mean age of PLWH increases, this population is at a greater risk of developing chronic conditions such as obesity, hypertension, cardiovascular disease, and diabetes, which are especially prevalent among PLWH. The risk of chronic diseases is of special concern for African Americans and Hispanics, who have a higher prevalence of diabetes and cardiovascular disease and associated risk factors, such as obesity and hypertension. Aging and HIV status compound these risks.

Initiation of ARV therapy has been reported to lead to weight gain within approximately the first year, with several studies reporting mean increases of a few kilograms and 20%-40% of patients shifting to a higher category of body mass index (BMI) (eg, normal to overweight, overweight to obese). Among ARV therapies, integrase strand transfer inhibitor (INSTI)-based regimens have been associated with greater weight gain than regimens based on protease inhibitors (PIs) or non-nucleoside reverse transcriptase inhibitor in real-world studies of treatment-naïve patients and patients who switch their ARV therapy to an INSTI-based regimen. Within the INSTI class, dolutegravir and bictegravir have been associated with greater weight gain than other INSTIs. Tenofovir alafenamide (TAF), a nucleoside reverse transcriptase inhibitor (NRTI) commonly included in ARV regimens, has also been associated with ARV-associated weight gain, especially in comparison to tenofovir disoproxil fumarate (TDF). However, the impact of TAF, particularly in relation to INSTI-based regimens, remains poorly understood. Nevertheless, data from recent clinical trials have demonstrated that even among regimens without TAF, INSTI-based regimens are associated with the greatest weight gain.

Importantly, ARV-related weight gain has been associated with increased risk for diabetes and cardiovascular disease among PLWH (myocardial infarction [MI], stroke, coronary conditions). Recent US Department of Health and Human Services guidelines highlight concerns related to weight gain associated with certain ARV therapies, such as INSTI-based regimens, and encourage providers to consider the tolerability profile of these agents when selecting an appropriate regimen and to monitor for weight gain. Current guidelines also specify that weight gain may be especially prevalent in certain patient populations (eg, women, African Americans, and Hispanics), consistent with recent reports of gender and racial differences in the risk of weight gain upon initiating INSTI-based regimens. Recent studies have shown that African Americans and women are at a higher risk of weight gain with INSTI-based regimens vs other regimens, but data specifically focused on African American females and Hispanics are lacking. Therefore, the current study aimed to understand the difference in weight gain among treatment-naïve female African American PLWH or Hispanic PLWH after initiating INSTI-based vs PI-based ARV regimens.

METHODS

Data Source

Patient-level records from the Optum® Pan-Therapeutic Deidentified Electronic Health Records (EHR) database were obtained. This database contains deidentified longitudinal data on diagnostic procedures, medications, laboratory results, outpatient visits, hospitalizations, clinical notes, and patient outcomes, primarily from integrated delivery networks for 80 million US patients (≥7 million patients from each census region).

Study Period and Population

The study period for this retrospective, observational, matched-cohort study was January 1, 2014, to December 31, 2019 (Figure 1). Female African American and male and female Hispanic PLWH with ≥1 written prescription for INSTI- or PI-based ARV regimens between January 1, 2015, and December 31, 2018, (intake period) were included. Index date was defined as the date of the earliest written ARV prescription during the intake period. Additional study inclusion criteria were: age ≥18 years at index, ≥365 days of EHR activity pre-/post-index, ≥1 diagnosis for HIV-1 during the year prior to index date (baseline period), and ≥1 baseline (between 12 months pre- and 30 days post-index) and follow-up (between 4th and 12th month post-index) measure for either weight or BMI. Exclusion criteria were: ≥1 HIV-2 diagnosis or any evidence of pregnancy during the study; ≥1 prescription for any ARV during the baseline period; ≥1 diagnosis for liver disease or chronic kidney disease (stage 4 and above) or ≥1 laboratory report for creatinine clearance <30 min/ml during the 12-month baseline period; and inconsistent/missing data on gender or birth year. Although it would be useful to analyze female Hispanics alone, sample size considerations did not allow this approach.

Identification of Index Regimen

Treatment-naïve patients with HIV-1 are generally treated with an ARV regimen comprising two nucleoside reverse transcriptase inhibitors (NRTIs) in combination with a third ARV agent from other ARV drug classes (INSTI, PI, or non-NRTI). Current ARV regimens are formulated as fixed-dose combinations (FDC) which contain a combination of two or more ARV agents in a single tablet, and

---

Figure 1. Study Design and Time Frame
multitablet regimen formulations. In the current study, INSTI- or PI-based regimens identified on the index date were defined as the index regimen. Patients were classified as INSTI initiators if the index ARV regimen included dolutegravir, raltegravir, bictegravir, or elvitegravir. Patients were classified as PI initiators if the index ARV regimen included atazanavir or darunavir. Patients not taking an FDC INSTI or PI were required to have prescriptions for ≥2 distinct NRTIs or ≥1 NRTI FDC within 14 days of the index date. Patients with >1 INSTI or PI drug identified on the index date were excluded.

Outcomes
An intent-to-treat approach was used to evaluate change in weight and BMI within 12 months post initiation of INSTI- vs PI-based regimens in treatment-naïve (1) female African Americans and (2) male and female Hispanics. The primary outcomes were absolute change and proportion of patients with ≥5% change in weight and BMI from baseline to follow-up. Secondary outcomes included proportion of patients with weight change ≥10 kg, ≥10%, ≥20%, and proportion of patients who shifted to a different BMI category. All outcomes were also evaluated by index BMI value category (<25 kg/m² vs. ≥25 kg/m²).

Variables
Variables included demographic characteristics (age, reported gender [for Hispanic cohort only], race [for Hispanic cohort only], region, insurance type, and index year), clinical characteristics (Quan-Charlson Comorbidity Index [QCI], comorbidities [see diagnostic codes in Table 1. Baseline Demographic and Clinical Characteristics for Female African American and Hispanic Patients] as well as comorbidities [see diagnostic codes in Table 1. Baseline Demographic and Clinical Characteristics for Female African American and Hispanic Patients] as well as comorbidities [see diagnostic codes in Table 1. Baseline Demographic and Clinical Characteristics for Female African American and Hispanic Patients].

### Table 1. Baseline Demographic and Clinical Characteristics for Female African American and Hispanic Patients

|                      | Female African American | Hispanic |
|----------------------|-------------------------|----------|
|                      | PI (weighted n=1703)    | INSTI (weighted n=1704) | | PI (weighted n=1846) | INSTI (weighted n=1865) | |
| **Age, mean (SD)**   | 47.2 (10.3)             | 46.9 (11.3) | 2.6% | 43.3 (10.9) | 43.0 (13.3) | 2.4% |
| **Female, n (%)**    | N/A                     | N/A       | N/A | 475 (25.7) | 462 (24.8) | 2.2% |
| **Race, n (%)**      |                         |           |     |           |           |      |
| African American     | N/A                     | N/A       | N/A | 51 (2.8)  | 101 (5.4)  | 13.6% |
| Asian                | N/A                     | N/A       | N/A | 0 (0.0)   | 6 (0.4)    | 8.3%  |
| Caucasian            | N/A                     | N/A       | N/A | 1126 (61.0) | 959 (51.4) | 19.5% |
| Other/unknown        | N/A                     | N/A       | N/A | 669 (36.2) | 799 (42.8) | 13.5% |
| **Insurance plan type, n (%)** |                 |           |     |           |           |      |
| Commercial           | 167 (9.8)               | 299 (17.6) | 22.8% | 291 (15.8) | 469 (25.2) | 23.5% |
| Medicaid             | 371 (21.8)              | 229 (13.4) | 22.0% | 81 (4.4)  | 169 (9.0)  | 18.6% |
| Medicare             | 164 (9.7)               | 69 (4.0)   | 22.4% | 68 (3.7)  | 85 (4.6)   | 4.5%  |
| Other                | 144 (8.5)               | 176 (10.4) | 6.5% | 439 (23.8) | 360 (19.3) | 18.1% |
| Missing              | 858 (50.3)              | 930 (54.6) | 8.6% | 967 (52.4) | 783 (42.0) | 20.9% |
| **Baseline weight, mean (SD)** |             |           |     |           |           |      |
| 83.2 (22.6)          | 82.8 (25.4)             | 2.0% | 77.2 (20.2) | 78.5 (18.1) | 7.1%  |
| **Baseline BMI, mean (SD)** |             |           |     |           |           |      |
| 30.6 (8.3)           | 30.8 (9.2)             | 2.0% | 27.2 (6.1) | 27.4 (6.1) | 2.7%  |
| **Baseline BMI category, n (%)** |             |           |     |           |           |      |
| Underweight (BMI<18.5) | 49 (2.9)              | 62 (3.7)   | 4.3% | 107 (5.8) | 54 (2.9)   | 14.4% |
| Normal (BMI 18.5-24.9) | 319 (18.7)             | 414 (24.3) | 13.6% | 526 (28.5) | 634 (34.0) | 11.9% |
| Overweight (BMI 25.0-29.9) | 464 (27.3)           | 389 (22.8) | 10.2% | 681 (36.9) | 608 (32.6) | 8.9%  |
| Obese (BMI ≥30)      | 806 (47.3)             | 776 (45.6) | 3.5% | 437 (23.7) | 502 (26.9) | 7.4%  |
| Missing              | 65 (3.8)               | 63 (3.7)   | 0.6% | 95 (5.1)  | 68 (3.6)   | 7.3%  |
| **Baseline comorbidities** |             |           |     |           |           |      |
| QCI score, mean (SD) | 3.2 (2.5)              | 3.2 (2.3)  | 1.0% | 3.1 (2.1) | 3.1 (2.2)  | 1.2%  |
| **No. of CVD risk conditions, mean (SD)** |             |           |     |           |           |      |
| 0.8 (1.0)           | 0.8 (1.0)             | 0.6% | 0.6 (0.9) | 0.5 (0.9) | 3.9%  |
| **Individual conditions, n (%)** |             |           |     |           |           |      |
| T2DM                 | 277 (16.2)             | 263 (15.4) | 2.2% | 239 (12.9) | 232 (12.5) | 1.5%  |
| Hypertension         | 522 (30.6)             | 620 (36.4) | 12.2% | 317 (17.2) | 310 (16.6) | 1.4%  |
| Hyperlipidemia       | 247 (14.5)             | 244 (14.3) | 0.5% | 337 (18.3) | 307 (16.5) | 4.7%  |
| AIDS                 | 1074 (63.0)            | 1127 (66.2) | 6.5% | 1222 (66.2) | 1283 (68.8) | 5.6%  |
| **No. of drugs used at baseline, mean (SD)** |             |           |     |           |           |      |
| 0.6 (1.0)           | 0.7 (1.2)             | 2.5% | 0.4 (0.7) | 0.4 (0.9) | 2.8%  |

Abbreviations: BMI, body mass index; CVD, cardiovascular diseases; INSTI, integrase inhibitors; PI, protease inhibitors; QCI, Quan Charlson Comorbidity Index; T2DM, type 2 diabetes mellitus.

* Standard difference, with |d| ≥10% being considered as significant.

* Includes Multiple, Uninsured, Unknown, or Other.
Supplemental Code Lists, and medication use (see medication codes in Supplemental Code Lists).

Data Analysis
Univariate statistics were used to descriptively analyze demographic characteristics, clinical characteristics, and outcomes of interest. Frequencies and percentages were reported for categorical variables; means and SD were reported for continuous variables.

Inverse probability of treatment weighting approach: The inverse probability of treatment weighting approach (IPTW) was used to control for selection bias and improve cohort comparability. To account for the effect on weight change from both the type of index regimen and the presence of TAF, IPTW was conducted in four treatment cohorts: PI with TAF, PI without TAF, INSTI with TAF and INSTI without TAF. A logistic regression model was used to calculate the propensity scores for each patient in the four treatment cohorts, with PI serving as the reference group for the generation of propensity scores. Independent variables in the model for female African Americans included age, baseline weight, baseline QCI, number of cardiovascular disease risk factors (prediabetes/glucose intolerance, type 2 diabetes, MI, congestive heart failure, hypertension and hyperlipidemia) at baseline and number of potentially weight-modifying drugs (diabetes therapies, psychiatric/neurologic therapies, hormone therapy/contraception, stimulants/appetite suppressants, and anti-hypertensives) used at baseline. Independent variables in the model for Hispanics included age, gender, baseline weight, baseline QCI, and number of potentially weight-modifying drugs used at baseline. Sample size considerations did not allow the inclusion of the number of cardiovascular risk factors as an independent variable for Hispanics, but inclusion of number of potentially weight-modifying drugs (especially diabetes therapies and antihypertensives) were used to serve as a proxy for cardiovascular risk. The inverse probability of treatment weight was calculated as the inverse of the propensity score. After the four treatment cohorts were balanced (standard difference <10%), PI with TAF and PI without TAF were grouped into one PI cohort. The same grouping was done for the INSTI cohort. The comparisons of outcomes were done between PI vs INSTI cohorts.

Outcome models: Multivariable regression models were used to compare the outcomes of interest between IPTW treatment cohorts. Ordinary least-squares models were used to model absolute and expected percent change in weight and BMI, as a function of the independent variable (INSTI- vs PI-based regimens) and covariates. P values and 95% confidence intervals (CI) were calculated. The expected proportion of patients having weight/BMI increases as a function of the independent variable (INSTI- vs. PI-regimens) and covariates was modeled using logistic regression. A P value <.05 was considered statistically significant for all analyses.

Analytical software: All analyses used SAS Enterprise Guide, version 7 (SAS Institute, Cary, NC).

RESULTS

Baseline Demographics and Characteristics of African American Females
Of the 7271 patients with ≥1 prescription for a INSTI-based or PI-based regimen during the intake period and ≥1 HIV-1 diagnosis within the prior 12 months, 852 were female African Americans (INSTI, 688; PI, 164). Baseline demographics and clinical characteristics between PI and INSTI cohorts were similar (Supplemental Table S1). IPTW was used to create weighted cohorts of similar size (INSTI, 1704; PI, 1703) that were balanced with regards to key baseline demographic and clinical variables (Table 1). Among the weighted INSTI and PI cohorts, mean age was 46.9 and 47.2 years, mean weight at baseline was 82.8 and 83.2 kg, and mean BMI at baseline was 30.8 and 30.6 kg/m², respectively. Mean time to follow-up weight measure was 295 days and 284 days (P=0.059) for the INSTI and PI cohorts, respectively. The INSTI and PI cohorts had the same mean QCI score (3.2) and mean number of cardiovascular conditions (0.8). Similar proportions had a baseline diagnosis of AIDS (INSTI, 66.2%; PI, 63.0%), hypertension (INSTI, 36.4%; PI, 30.6%), type 2 diabetes (INSTI, 15.4%; PI, 16.2%) or hyperlipidemia (INSTI, 14.3%; PI, 14.5%). Among those with insurance plan information, the most common types were Medicaid (INSTI, 13.4%; PI, 21.8%) and Commercial (INSTI, 17.6%; PI, 9.8%).

| Table 2. Index BMI Category and Proportion of African American Female Patients With BMI Category Shifts During Follow-up |
|---------------------------------------------------------------|
| **Index BMI Category** | **PI-Based Regimens: Post-index BMI Category, n (%)** | **INSTI-Based Regimens: Post-index BMI Category, n (%)** |
|------------------------|---------------------------------------------------------------|
| Underweight (BMI <18.5), n=49 | Underweight, n=23 | Normal, n=360 | Overweight, n=556 | Obese, n=699 |
| 8 (16.3) | 38 (77.6) | 0 (0.0) | 3 (6.1) |
| Normal (BMI 18.5-24.9), n=319 | 15 (4.7) | 237 (74.3) | 60 (18.8) | 7 (2.2) |
| Overweight (BMI 25.0-29.9), n=464 | 0 (0.0) | 85 (18.3) | 359 (77.4) | 20 (4.3) |
| Obese (BMI ≥30), n=806 | 0 (0.0) | 0 (0.0) | 137 (17.0) | 669 (83.0) |
| **Index BMI Category** | **Underweight, n=43** | **Normal, n=359** | **Overweight, n=440** | **Obese, n=798** |
| Underweight (BMI <18.5), n=62 | 19 (30.6) | 41 (66.1) | 2 (3.2) | 0 (0.0) |
| Normal (BMI 18.5-24.9), n=414 | 24 (5.8) | 265 (64.1) | 96 (23.3) | 28 (6.8) |
| Overweight (BMI 25.0-29.9), n=389 | 0 (0.0) | 47 (12.1) | 275 (70.7) | 67 (17.2) |
| Obese (BMI ≥30), n=776 | 0 (0.0) | 6 (0.8) | 67 (8.6) | 703 (90.6) |

Abbreviations: BMI, body mass index; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor.
*Proportions reflect total for each row.
Among the INSTI cohort, 62 (3.6%) were underweight at baseline, 414 (24.3%) had normal body weight, 389 (22.8%) were overweight, and 776 (45.5%) were obese (BMI ≥30 kg/m²). Among the PI cohort, 49 (2.9%) patients were underweight at baseline (BMI <18.5 kg/m²), 319 (18.7%) had normal body weight (BMI 18.5-24.9 kg/m²), 464 (27.2%) were overweight (BMI 25.0-29.9 kg/m²), and 806 (47.3%) were obese (Table 2).

### Weight and BMI Changes in African American Females

After a mean follow-up of ~9.5 months, African American females initiating INSTI-based regimens had a 1.5 kg greater mean weight gain (2.1 kg vs 0.6 kg; P=0.033) and a 0.6 kg/m² greater mean BMI increase (0.6 kg/m² vs 0.0 kg/m²; P=0.028), compared with PI initiators (Figure 2A). When stratified by the presence of TAF, the mean ± SD weight gain was 2.6±17.7 kg vs 1.6±12.2 kg for those initiating INSTI-based regimens with or without TAF, respectively. The mean ± SD weight gain was 1.5±54.1 kg vs ~0.3±29.8 kg for those initiating PI-based regimens with or without TAF, respectively (data not shown). Similarly, a greater proportion of INSTI initiators experienced ≥5% weight gain (32% vs 29%; OR=1.2; 95% CI [1.0–1.4]), ≥10% weight gain (18% vs 14%; OR=1.3; 95% CI [1.1–1.5]), or ≥10 kg weight gain (13% vs 10%; OR=1.3; 95% CI [1.1–1.6]) than PI initiators (Figure 3A).

### BMI Category Shifts in African American Females

Among female African American INSTI initiators with normal baseline weight, 23.3% became overweight (BMI ≥25 kg/m²) and 6.8% became obese (BMI ≥30 kg/m²) during follow-up. Among normal-weight PI initiators, 18.8% and 2.2% became overweight or obese, respectively, during follow-up. Among overweight INSTI initiators, 17.2% became obese during follow-up, as compared with 4.3% of PI initiators (Table 2).

### Weight and BMI Changes in African American Females by Baseline BMI

Among female African Americans with baseline BMI <25 kg/m² or ≥25 kg/m², there were no significant differences between INSTI and PI initiators regarding the primary endpoints, ie, mean change in weight or BMI (Supplemental Figure S1) or proportion experiencing ≥5% increase in weight (Supplemental Figure S2).

### Baseline Demographic and Clinical Characteristics for Hispanics

Of the 7,271 patients with ≥1 prescription for an INSTI or PI-based regimen during the intake period and ≥1 HIV-1 diagnosis within the prior 12 months, 932 patients were Hispanic (INSTI, 783; PI, 149). Baseline demographics and clinical characteristics between INSTI and PI cohorts were similar (Supplemental Table S2).

### Abbreviations

- BMI: body mass index
- INSTI: integrase strand transfer inhibitor
- PI: protease inhibitor
- IPTW: inverse probability of treatment weighting

### Table 3

| Index BMI Category | PI-Based Regimens: Post-index BMI Category, n (%)<sup>a</sup> |
|--------------------|---------------------------------------------------------------|
|                    | Underweight, n=109 | Normal, n=533 | Overweight, n=643 | Obese, n=466 |
| Underweight (BMI <18.5), n=107 | 78 (72.7) | 29 (27.3) | 0 (0.0) | 0 (0.0) |
| Normal (BMI 18.5-24.9), n=526 | 12 (2.3) | 344 (65.4) | 166 (31.5) | 4 (0.8) |
| Overweight (BMI 25.0-29.9), n=681 | 19 (2.8) | 156 (22.9) | 439 (64.5) | 67 (9.8) |
| Obese (BMI ≥30), n=437 | 0 (0.0) | 4 (0.8) | 38 (8.7) | 395 (90.5) |

| Index BMI Category | INSTI-Based Regimens: Post-index BMI Category, n (%)<sup>a</sup> |
|--------------------|---------------------------------------------------------------|
|                    | Underweight, n=31 | Normal, n=588 | Overweight, n=607 | Obese, n=570 |
| Underweight (BMI <18.5), n=54 | 21 (38.6) | 20 (38.2) | 12 (23.2) | 0 (0.0) |
| Normal (BMI 18.5-24.9), n=634 | 8 (1.2) | 482 (76.1) | 132 (20.9) | 12 (1.8) |
| Overweight (BMI 25.0-29.9), n=608 | 2 (0.3) | 77 (12.6) | 411 (67.6) | 118 (19.4) |
| Obese (BMI ≥30), n=502 | 0 (0.0) | 9 (1.9) | 52 (10.4) | 440 (87.7) |

**Abbreviations:** BMI, body mass index; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor.

**P<0.05.**
create weighted cohorts of similar size (INSTI, 1865; PI, 1846) that were balanced with regard to key baseline demographic and clinical variables (Table 1). Among the weighted INSTI and PI cohorts, mean age was 43.0 and 43.3 years, and 24.8% and 25.7% were females, respectively. Male and female Hispanics were not analyzed separately due to sample size considerations. Mean weight at baseline was 78.5 and 77.2 kg, and mean BMI at baseline was 27.4 and 27.2 kg/m², respectively. Mean time to follow-up weight measure was 284 days and 282 days (P=0.733) for the INSTI and PI cohorts, respectively. The INSTI and PI cohorts had the same mean QCI score (3.1) and similar number of mean cardiovascular conditions (0.5 vs 0.6). Similar proportions had a baseline diagnosis of AIDS (INSTI, 68.8%; PI, 66.2%), hypertension (INSTI, 16.6%; PI, 17.2%), type 2 diabetes (INSTI, 12.5%; PI, 12.9%) or hyperlipidemia (INSTI, 16.5%; PI, 18.3%). Information about plan type was missing for 42.0% and 52.4% of INSTI and PI-based cohorts, respectively. Among those with insurance plan information, the most common types were Commercial (INSTI, 25.2%; PI, 15.8%) and Other, which included Multiple, Uninsured, Unknown, or Other (INSTI, 19.3%; PI, 23.8%).

Among the INSTI cohort, 54 (2.9%) were underweight at baseline, 634 (34.0%) had normal bodyweight, 608 (32.6%) were overweight, and 502 (26.9%) were obese (BMI ≥30 kg/m²). Among the PI cohort, 107 (5.8%) were underweight at baseline (BMI: <18.5 kg/m²), 526 (28.5%) had normal bodyweight (BMI: 18.5–24.9 kg/m²), 681 (36.9%) were overweight (BMI: 25.0–29.9 kg/m²), and 437 (23.7%) were obese (Table 3).

**Weight and BMI Changes in Hispanics**

After a mean follow-up of ~9.5 months, Hispanic patients initiating INSTI or PI-based regimens had similar mean increases in weight (2.1 and 1.8 kg, respectively) and BMI (0.7 and 0.6 kg/m², respectively) (Figure 2B). When stratified by the presence of TAF, the mean ± SD weight gain was 2.5±7.9 kg and 1.8±7.1 kg for those initiating INSTI-based regimens with or without TAF, respectively. The mean ± SD weight gain was 2.9±6.8 kg and 0.6±7.3 kg for those initiating PI-based regimens with or without TAF, respectively (data not shown). INSTI initiators were more likely than PI initiators to experience ≥5% weight gain (31% vs 27%; OR=1.2; 95% CI [1.1-1.4]) (Figure 3B) or ≥5% BMI increase (30% vs 26%; OR=1.2; 95% CI [1.0-1.4]) (data not shown), but less likely to experience weight gains ≥20% (5% vs 9%; OR=0.5; 95% CI [0.4-0.7]) or ≥10 kg (11% vs 14%; OR=0.8; 95% CI [0.6-0.9]) (Figure 3B).

**Figure 3.** Odds Ratio of Weight Gain in Female African Americans (A) or Hispanics (B)

| Odds Ratio (95% CIs); p-value | Proportion of Patients with Endpoint (PI: INSTI) |
|------------------------------|-----------------------------------------------|
| ≥5% weight gain               | 1.19 (1.03, 1.37); p=0.037* (29%; 32%)     |
| ≥10% weight gain              | 1.28 (1.07, 1.54); p=0.008* (14%; 18%)      |
| ≥20% weight gain              | 1.23 (0.94, 1.60); p=0.133 (6%; 8%)        |
| ≥10 kg weight gain            | 1.32 (1.07, 1.63); p=0.009* (10%; 13%)     |

Abbreviations: CIs, confidence intervals; INSTI, integrase strand transfer inhibitor; PI, protease inhibitor.

* P<0.05.
BMI Category Shifts in Hispanics
Among Hispanic INSTI initiators with normal baseline weight, 20.9% became overweight (BMI ≥25 kg/m²) and 1.8% became obese (BMI ≥30 kg/m²) during follow-up. Among normal weight PI initiators, 31.5% and 0.8% became overweight or obese, respectively, during follow-up. Among overweight INSTI initiators, 19.4% became obese during follow-up, as compared with 9.8% of PI initiators (Table 3).

Weight and BMI Changes in Hispanics by Baseline BMI
Among Hispanic patients with baseline BMI <25 kg/m², PI initiators had a 1.7 kg greater mean weight gain (4.2 kg vs 2.5 kg; P<0.035), but a similar mean BMI increase (1.4 kg/m² vs 1.0 kg/m²; P=0.158), compared with INSTI initiators (Supplemental Figure S3A). In contrast, Hispanic patients with baseline BMI ≥25 kg/m² who initiated INSTI-based regimens had 1.6 kg greater mean weight gain (2.0 kg vs 0.3 kg; P=0.005) and 0.5 kg/m² greater mean BMI increase (0.5 kg/m² vs 0.1 kg/m²; P=0.043), compared with PI initiators (Supplemental Figure S3B).

Among Hispanic patients with baseline BMI <25 kg/m², INSTI initiators were less likely than PI initiators to experience ≥5% weight gain (34% vs 48%; OR=0.8; 95% CI [0.6-1.0]) (Supplemental Figure S4A) or ≥5% increase in BMI (34% vs 39%; OR=0.8; 95% CI [0.6-1.0]) (data not shown). In contrast, among patients with baseline BMI ≥25 kg/m², a greater proportion of INSTI initiators experienced ≥5% weight gain (30% vs 21%; OR=1.6; 95% CI [1.3-2.0]) (Supplemental Figure S4B) or ≥5% increase in BMI (30% vs. 21%; OR=1.6; 95% CI [1.3-1.9]) (data not shown).

DISCUSSION
After a mean ~9.5-month follow-up, female African American INSTI initiators had a 1.5 kg greater mean weight gain, 0.6 kg/m² greater mean BMI increase, and greater odds of ≥5% weight gain or ≥5% BMI increase vs PI initiators. Similar trends were observed in female African Americans for weight gains ≥10 kg or ≥10%; however, differences were not significant for ≥20% weight gain, possibly due to the small number of participants with extreme gains. In the Hispanic study population, mean weight gain was not significantly different between regimens (INSTI, 2.1 kg; PI, 1.8 kg), although the risk of ≥5% weight gain was greater for INSTI initiators vs PI initiators, while the risk of ≥20% or ≥10 kg weight gain was lower in INSTI initiators than PI initiators. INSTI initiators with baseline BMI ≥25 kg/m² had greater absolute mean weight gain and BMI increase than PI initiators for both study populations, whereas for INSTI initiators with baseline BMI ≥25 kg/m², absolute mean weight gain and BMI increases were higher for female African Americans and lower for Hispanics. The majority of subjects in our study were overweight (female African Americans, 70%; Hispanics, 60%), underscoring the potential importance of our findings. Moreover, hypertension (female African Americans, 33%; Hispanics 17%) and type 2 diabetes (female African Americans, 16%; Hispanics, 13%), which are important risk factors for complications such as MI, stroke, and chronic renal disease, were common in our study population, consistent with reports of their high prevalence in PLWH.6-7

A similar real-world study using a different database reported a higher risk of 5% weight gain for INSTI vs. PI initiators overall (1.5 kg greater weight gain for INSTI), but the differences did not reach statistical significance among females, perhaps due to smaller sample size.28 In a pooled analysis of 8 clinical trials, Sax et al reported approximately 1.5 kg greater mean weight gain for INSTIs vs. PIs, with female and African Americans/Black patients having greater risk of ≥10% weight gain.29 Similarly, a recent prospective, observational study by Kline et al of military personnel with HIV reported that overweight African American men initiating INSTI-based regimens had greater mean BMI increase at 2 years than overweight White men (1.85 kg/m²y, P = 0.007).20 Lake et al recently reported that among virally suppressed PLWH who switched to INSTI regimens, Black race and female sex were associated with greater weight gain.28

However, the literature reports inconsistent results regarding baseline BMI as a risk factor for ARV-related or INSTI-related weight gain. Kline et al found no significant difference in weight gain between regimens among men with baseline BMI ≤25 kg/m².31 In contrast, a study from the Women's Interagency HIV Study (WIHS) reported that BMI ≤30 kg/m² was a risk factor for greater weight gain among those using INSTI-based regimens.22 Similarly, our study found a greater risk of 10%, 20%, or 10 kg weight gain for African American females with baseline BMI ≤25 kg/m², but not among those with BMI ≥25 kg/m². However, Lake et al found that BMI ≤30 kg/m² at switch was associated with greater weight gain among women.28

Unlike female African Americans, mean differences between regimens among Hispanics did not reach statistical significance and contrasting results were observed for subgroups with baseline BMI ≤25 or ≥25 kg/m². The literature also shows conflicting results regarding risk of weight gain among Hispanics, with reports showing either similar20,21 or greater risk22 as compared with non-Hispanic whites. As in most of the literature, the present study examined a Hispanic study population that reported a variety of racial backgrounds (approximately 56% white, 40% other/unknown, and 4% African American), and diverse ancestry among Hispanic PLWH has been associated with differing HIV care outcomes.25 Indeed, a recent study has shown differences in weight gain within White, Black, or Hispanic cohorts who switch to INSTI-based regimens may be associated with differences in genetic markers related to ancestry; however, the study sample included too few people of Hispanic ethnicity to draw firm conclusions.25 Interpretation of our results is also complicated by the inclusion of both females (25%) and males (75%) in the Hispanic study population. As mentioned previously, several studies have reported differences between genders in ARV-related weight gain.20-21 Although the sample size of Hispanic PLWH in our study was not sufficient to allow separate analysis of males and females, the impact of sex on weight gain should be explored in future studies. Another factor that may explain the differing results for the female African American and Hispanic cohorts is differences in type and quality of health care received by these two study populations; in the present study, female African Americans were more likely to have Medicare/Medicaid coverage and Hispanics were more likely to have Commercial insurance or Other insurance (which includes none). However, due to the large proportion of missing data for insurance plan type (approximately 50%) in our study population, further research would be required to explore this hypothesis. Lastly, in our study, the Hispanic cohort was younger, had fewer comorbidities, and had lower baseline weight than the African American females, which may also have affected the differences in weight gain.

It is possible that differences in weight gain between regimens may be related to differences in “return to health,” a well-documented phenomenon among newly treated PLWH.20,21 However, our cohorts were well-balanced on demographic and clinical variables and...
Lastly, regardless of HIV status, excess body weight may have a negative impact on adherence to ARV regimens. For example, a 2009 study using WHS data showed that self-perception of fat gain in the abdomen was the strongest predictor of nonadherence to ARV regimens, especially among African American females. It is especially concerning since adherence to ARV regimens has been shown to lower among non-White PLWH (especially African Americans) as compared with White PLWH, and low adherence is known to be associated with decreased viral suppression and increased risk of drug resistance. Lastly, regardless of HIV status, excess body weight is associated with higher health care costs, thus contributing to additional burden for women and minorities.

This real-world study supplements the current literature by focusing on subgroups of PLWH (female African Americans and Hispanics), who are at high risk of weight gain due to the presence of certain comorbidities (hypertension, obesity, and type 2 diabetes) and other health care disparities. The Optum EHR database comprises data from a geographically diverse group of provider networks in the United States and includes variables (eg, bodyweight, BMI) that are often absent from other real-world data sources. This study measured a variety of clinically meaningful endpoints such as absolute weight/BMI increase, proportion with weight gain ≥10 kg, ≥5%, ≥10%, or ≥20% of total body weight, and assessed outcomes overall and by BMI category. Another strength of this study is the IPTW approach, which was used to control for selection bias and improve cohort comparability. IPTW was performed separately for treatment cohorts with and without TAF and to control for the effect of TAF, which has been independently associated with weight gain. Consistent with the literature, we observed greater weight gain among patients initiating regimens with TAF vs without TAF (for both INSTI- or PI-based regimens), although the number of patients using PI-based regimens with TAF was insufficient to perform a formal comparison. Studies with a larger sample size are needed to assess the impact on weight gain for TAF vs tenofovir isopropyl fumarate in ARV regimens.

This study has some limitations. Prescription records from EHR do not necessarily indicate whether the patient filled a prescription or took the medication. Although steps were taken to ensure patients were newly initiating ARV, the first HIV diagnosis or ARV prescription observed in the database may not correspond to the patient’s first diagnosis, since patients may have had gaps in care or switched from a provider that does not provide data to the Optum EHR database. In addition, there are various factors that may impact treatment choice and/or risk of weight gain, such as income, education, geographic location, rural/urban location, and behavioral factors, but that are not available in the data and could not be controlled. However, we included in the model key factors that would be expected to impact the choice of HIV treatment, namely, comorbid conditions and concomitant medications. Lastly, due to sample size limitations, composite scores were used to reflect aggregated drug classes, which may have masked differences between individual drugs.

CONCLUSIONS

In this observational study using EHR from a large, geographically representative US database, INSTI-based regimens were associated with greater absolute weight gain and greater risk of 5% weight gain among treatment-naïve female African Americans vs PI-based regimens. Among Hispanics, risk of 5% weight gain was greater for INSTI-based vs PI-based regimens, but changes in absolute weight gain were not significantly different. This study also demonstrated a high prevalence of obesity and other cardiovascular/metabolic comorbidities among female African Americans and Hispanics, which are likely to have an important health impact in these high-risk populations. Although additional studies with greater sample sizes and longer follow-up time are needed, the present results support recommendations to monitor weight changes among PLWH initiating INSTI-based regimens and may also inform treatment choice for patients who are at risk for ARV-related weight gain.

Acknowledgments: The authors wish to thank Wing Chow for her contributions to study design. Ajaybir Singh, Mu Sigma Business Solutions Pvt. Ltd., Bengaluru, India, provided data programming support. Leo J. Philip Tharappel and Sandeep Kumar Vishwakarma, SIRO Clinpharm, Mumbai, India, provided writing support. This work was funded by Janssen Scientific Affairs, LLC, USA.

Author Contributions: Drs. Y-WC, DA, CDP, and PD were involved in study design, analysis, and interpretation. Y-WC performed the statistical analyses. All authors had full access to all study data and take responsibility for data integrity and accuracy of data analysis. All authors meet ICMJE criteria and all those fulfilling criteria are listed as authors. All authors provided input on the manuscript, made the final decision about where to publish these data, and approved submission to this journal.

Conflicts of Interest: Drs. Y-WC, DA, CDP, and PD are employees of Janssen Scientific Affairs, LLC. All authors hold stock in Johnson & Johnson, of which Janssen Scientific Affairs is a wholly-owned subsidiary.

Funding: This work was funded by Janssen Scientific Affairs, LLC, USA.

REFERENCES

1. CDC. HIV Surveillance Report, 2019. Vol. 32. May 2021. Accessed 23 September 2021. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
2. Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. Jul 22 2013;173(14):1337-44. doi:10.1001/jamainternmed.2013.6841
3. Trickey A, May M. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. Aug 2017;4(8):e349-e356. doi:10.1016/S2352-3018(17)30066-8
4. Oliaya O, Weiser J, Zhou W, Patel P, Bradley H. Hypertension among persons living with HIV in medical care in the United States-medical monitoring project, 2013-2014. Open Forum Infect Dis. Mar 2018;5(3):ofy028. doi:10.1093/ofid/ofy028
5. Herrin M, Tate JP, Akgun KM, et al. Weight gain and incidence of diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. Oct 1 2016;73(2):228-36. doi:10.1097/QAI.0000000000001071

6. Kong AM, Pozen A, Anastos K, Kelvin EA, Nash D. Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis. AIDS Patient Care STDS. Mar 2019;33(3):93-103. doi:10.1089/apc.2018.0190

7. Duncan AD, Goff LM, Peters BS. Type 2 diabetes prevalence and its risk factors in HIV: a cross-sectional study. PLoS One. 2018;13(3):e0194199-e0194199. doi:10.1371/journal.pone.0194199

8. Achhra AC, Mocroft A, Reiss P, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. Apr 2016;17(4):255-68. doi:10.1111/hiv.12294

9. Cook MJ, Bellou E, Bowes J, et al. The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology (Oxford). Dec 1 2018;57(12):2172-2182. doi:10.1093/rheumatology/key224

10. Aguayo-Mazzucato C, Diaque P, Hernandez S, Rosas S, Kostic M, Caballero AE. Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States. Diabetes Metab Res Rev. Feb 2019;35(2):e3097. doi:10.1002/dmrr.3097

11. Chatterjee R, Maruthur NM, Edelman D. Novel risk factors for type 2 diabetes in African-Americans. Curr Diab Rep. Dec 2015;15(12):103. doi:10.1007/s11892-015-0675-5

12. Musemwa N, Gadegbeku CA. Hypertension in African Americans. Curr Cardiol Rep. Oct 28 2017;19(12):129. doi:10.1007/s11886-017-0933-z

13. Bennett A, Parpo P, Krim SR. Hypertension and ethnicity. Curr Opin Cardiol. Jul 2016;31(4):381-6. doi:10.1097/HCC.0000000000000293

14. National Center for Health Statistics. Summary health statistics for U.S. adults—2019. Accessed September 23, 2021. https://www.cdc.gov/nchs/data/SHSDataQueryTool/SHS_adult/.

15. Koethe JR, Jenkins CA, Lau B, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res Hum Retroviruses. Jan 2016;32(1):50-8. doi:10.1097/aid.2015.0147

16. Bakal DR, Coelho LE, Luz PM, et al. Obesity following ART initiation is common and influenced by both traditional and HIV-ART-specific risk factors. J Antimicrob Chemother. Aug 1 2018;73(8):2177-2185. doi:10.1093/jac/dky145

17. Bourgi K, Jenkins CA, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Journal of the International AIDS Society. 2020;23(4):e25484. doi:10.1002/jia2.25484

18. Bourgi K, Rebeiro PF, Turner M, et al. Greater weight gain in treatment-naïve persons Starting Dolutegravir-Based Antiretroviral Therapy. Clin Infect Dis. May 17 2019. doi:10.1093/cid/ciz407

19. Galdámez R, García JA, Fernández M, et al. Short-term increase in risk of overweight and Concomitant systolic blood pressure elevation in treatment-naïve persons starting INSTI-based antiretroviral therapy. Open Forum Infect Dis. Dec 2019;6(12):sof491. doi:10.1093/ofid/ofz491

20. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. Oct 14 2020;71(6):1379-1389. doi:10.1093/cid/ciaa299

21. Norwood J, Turner M, Bobill C, et al. Brief Report: Weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. Dec 15 2017;76(5):527-531. doi:10.1097/QAI.0000000000001525

22. Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase strand transfer inhibitor use in women. Clin Infect Dis. 07 2020;71(3):593-600. doi:10.1093/cid/cia583

23. Venter WDF, Mothurese M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. Aug 29 2019;381(9):803-815. doi:10.1056/NEJMoa1902824

24. Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33(1):10-19. doi:10.1097/QCO.0000000000000616

25. Calmy A, Tovar Sanchez T, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. 2020;2352-3018 (Electronic)

26. DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. June 3, 2021, Accessed September 23, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adulthead/AdolAECGL.pdf

27. Debroy P, Sim M, Erlandson KM, et al. Progressive increases in fat mass occur in adults living with HIV on antiretroviral therapy, but patterns differ by sex and anatomic depot. J Antimicrob Chemother. Apr 1 2019;74(4):1028-1034. doi:10.1093/jac/dky551

28. Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. Clin Infect Dis. Feb 26 2020. doi:10.1093/cid/ciaa177

29. Chen YW, Hardy H, Periconi CD, Chow W. Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors. J Health Econ Outcomes Res. 2020;7(2):102-110. doi:10.36469/jheor.2020.13457

30. Chow W, Donga P, Côté-Sergent A, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Curr Med Res Opin. 2020/08/02 2020;36(8):1313-1323. doi:10.1080/03007995.2020.1775074

31. Kline MDA, Daniels C, Xu X, et al. Antiretroviral therapy anchor-based trends in body mass index following treatment initiation among military personnel with HIV. 2021;(1930-613X (Electronic)

32. De Meke HB, Luo Q, Luna-Gierke RE, et al. HIV care outcomes among Hispanics/Latinos with diagnosed HIV in the United States by place of birth-2015-2018. Medical Monitoring Project. Int J Environ Res Public Health. 2019;17(1):171. doi:10.3390/ijerph17010171

33. Erlandson KM, Wu K, Lake JE, et al. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. AIDS. Mar 1 2021;35(3):439-445. doi:10.1097/qad.0000000000002771
34. Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. *Front Endocrinol (Lausanne)*. 2018;9:705. doi:10.3389/fendo.2018.00705

35. Yuh B, Tate J, Butt A, et al. Weight change after antiretroviral therapy and mortality. *Clin Infect Dis*. 2015;60(12):1852-1859. doi:10.1093/cid/civ192

36. Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the Women’s Interagency HIV Study. 2009;(1573-3254 (Electronic))

37. Simoni JM, Huh D, Wilson IB, et al. Racial/Ethnic disparities in ART adherence in the United States: findings from the MACH14 study. 2012;(1944-7884 (Electronic))

38. Silverberg M, Leyden W, Quesenberry CJ, Horberg M. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. *J Gen Intern Med*. 2009;24(9):1065-72.

39. Geter A, Sutton MY, Armon C, Buchacz K. Disparities in viral suppression and medication adherence among women in the USA, 2011-2016. *AIDS Behav*. Nov 2019;23(11):3015-3023. doi:10.1007/s10461-019-02494-9

40. Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the United States by age and sex. *PLoS One*. 2021;16(3):e0247307. doi:10.1371/journal.pone.0247307